{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T02:45:29Z","timestamp":1793501129190,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100020956","name":"Merck Healthcare KGaA","doi-asserted-by":"publisher","award":["Crossref Funder ID: 10.13039\/100009945"],"award-info":[{"award-number":["Crossref Funder ID: 10.13039\/100009945"]}],"id":[{"id":"10.13039\/100020956","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40120-026-00897-0","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T10:23:30Z","timestamp":1773138210000},"page":"1491-1507","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Stability in Cognition and Employment in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two-year Phase IV CLARIFY-MS Study"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3824-2796","authenticated-orcid":false,"given":"Bruno","family":"Brochet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1128-7417","authenticated-orcid":false,"given":"Dawn","family":"Langdon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9543-4359","authenticated-orcid":false,"given":"Eva Kubala","family":"Havrdova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3850-447X","authenticated-orcid":false,"given":"Jeanette","family":"Lechner-Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0098-9918","authenticated-orcid":false,"given":"Xavier","family":"Montalban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6923-0846","authenticated-orcid":false,"given":"Francesco","family":"Patti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8329-5219","authenticated-orcid":false,"given":"Fredrik","family":"Piehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9930-7579","authenticated-orcid":false,"given":"Alessandra","family":"Solari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2106-2158","authenticated-orcid":false,"given":"Raymond","family":"Hupperts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9806-8358","authenticated-orcid":false,"given":"Nektaria","family":"Alexandri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1083-9796","authenticated-orcid":false,"given":"Annette","family":"Lehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7794-112X","authenticated-orcid":false,"given":"Andrzej","family":"Smyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1213-7218","authenticated-orcid":false,"given":"Krzysztof","family":"Selmaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"CLARIFY-MS Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"issue":"6","key":"897_CR1","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1177\/1352458511431076","volume":"18","author":"DW Langdon","year":"2012","unstructured":"Langdon DW, Amato MP, Boringa J, Brochet B, Foley F, Fredrikson S, et al. Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS). Mult Scler. 2012;18(6):891\u20138.","journal-title":"Mult Scler"},{"issue":"Suppl 200","key":"897_CR2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/ane.12656","volume":"134","author":"M Muckschel","year":"2016","unstructured":"Muckschel M, Beste C, Ziemssen T. Immunomodulatory treatments and cognition in MS. Acta Neurol Scand. 2016;134(Suppl 200):55\u20139.","journal-title":"Acta Neurol Scand"},{"issue":"11","key":"897_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-041249","volume":"10","author":"I Gil-Gonzalez","year":"2020","unstructured":"Gil-Gonzalez I, Martin-Rodriguez A, Conrad R, Perez-San-Gregorio MA. Quality of life in adults with multiple sclerosis: a systematic review. BMJ Open. 2020;10(11):e041249.","journal-title":"BMJ Open"},{"issue":"6","key":"897_CR4","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1017\/cjn.2022.334","volume":"50","author":"SA Morrow","year":"2023","unstructured":"Morrow SA, Baldwin C, Alkabie S. Importance of identifying cognitive impairment in multiple sclerosis. Can J Neurol Sci. 2023;50(6):813\u20139.","journal-title":"Can J Neurol Sci"},{"issue":"7","key":"897_CR5","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1080\/13854046.2010.511272","volume":"24","author":"SA Morrow","year":"2010","unstructured":"Morrow SA, Drake A, Zivadinov R, Munschauer F, Weinstock-Guttman B, Benedict RHB. Predicting loss of employment over three years in multiple sclerosis: clinically meaningful cognitive decline. Clin Neuropsychol. 2010;24(7):1131\u201345.","journal-title":"Clin Neuropsychol"},{"key":"897_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-016-1532-1","volume":"16","author":"E Jones","year":"2016","unstructured":"Jones E, Pike J, Marshall T, Ye X. Quantifying the relationship between increased disability and health care resource utilization, quality of life, work productivity, health care costs in patients with multiple sclerosis in the US. BMC Health Serv Res. 2016;16:294.","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"897_CR7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1177\/1359105317691587","volume":"24","author":"DS Dorstyn","year":"2019","unstructured":"Dorstyn DS, Roberts RM, Murphy G, Haub R. Employment and multiple sclerosis: a meta-analytic review of psychological correlates. J Health Psychol. 2019;24(1):38\u201351.","journal-title":"J Health Psychol"},{"issue":"1","key":"897_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13317-019-0117-5","volume":"10","author":"A Andravizou","year":"2019","unstructured":"Andravizou A, Dardiotis E, Artemiadis A, Sokratous M, Siokas V, Tsouris Z, et al. Brain atrophy in multiple sclerosis: mechanisms, clinical relevance and treatment options. Autoimmun Highlights. 2019;10(1):7.","journal-title":"Autoimmun Highlights"},{"issue":"22","key":"897_CR9","doi-asserted-by":"publisher","first-page":"e2373","DOI":"10.1212\/WNL.0000000000009522","volume":"94","author":"NC Landmeyer","year":"2020","unstructured":"Landmeyer NC, Burkner PC, Wiendl H, Ruck T, Hartung HP, Holling H, et al. Disease-modifying treatments and cognition in relapsing-remitting multiple sclerosis: a meta-analysis. Neurology. 2020;94(22):e2373\u201383.","journal-title":"Neurology"},{"issue":"4","key":"897_CR10","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1001\/jamaneurol.2020.4920","volume":"78","author":"E De Meo","year":"2021","unstructured":"De Meo E, Portaccio E, Giorgio A, Ruano L, Goretti B, Niccolai C, et al. Identifying the distinct cognitive phenotypes in multiple sclerosis. JAMA Neurol. 2021;78(4):414\u201325.","journal-title":"JAMA Neurol"},{"key":"897_CR11","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.msard.2018.09.018","volume":"26","author":"L Clemens","year":"2018","unstructured":"Clemens L, Langdon D. How does cognition relate to employment in multiple sclerosis? A systematic review. Mult Scler Relat Disord. 2018;26:183\u201391.","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"897_CR12","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1007\/s00415-012-6705-1","volume":"260","author":"A Ruet","year":"2013","unstructured":"Ruet A, Deloire M, Hamel D, Ouallet JC, Petry K, Brochet B. Cognitive impairment, health-related quality of life and vocational status at early stages of multiple sclerosis: a 7-year longitudinal study. J Neurol. 2013;260(3):776\u201384.","journal-title":"J Neurol"},{"issue":"11","key":"897_CR13","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1136\/jnnp-2018-318228","volume":"89","author":"J Chen","year":"2018","unstructured":"Chen J, Taylor BV, Blizzard L, Simpson S Jr., Palmer AJ, van der Mei IAF. Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data. J Neurol Neurosurg Psychiatry. 2018;89(11):1200\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"897_CR14","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1056\/NEJMoa0902533","volume":"362","author":"G Giovannoni","year":"2010","unstructured":"Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sorensen P, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):416\u201326.","journal-title":"N Engl J Med"},{"issue":"12","key":"897_CR15","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1177\/1352458517727603","volume":"24","author":"G Giovannoni","year":"2018","unstructured":"Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan K, Rieckmann P, Comi G, et al. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. Mult Scler. 2018;24(12):1594\u2013604.","journal-title":"Mult Scler"},{"issue":"14","key":"897_CR16","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1177\/13524585231205962","volume":"29","author":"B Brochet","year":"2023","unstructured":"Brochet B, Solari A, Lechner-Scott J, Piehl F, Langdon D, Hupperts R, et al. Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: the CLARIFY-MS study. Mult Scler. 2023;29(14):1808\u201318.","journal-title":"Mult Scler"},{"key":"897_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103385","volume":"57","author":"B Brochet","year":"2022","unstructured":"Brochet B, Hupperts R, Langdon D, Solari A, Piehl F, Lechner-Scott J, et al. Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis. Mult Scler Relat Disord. 2022;57:103385.","journal-title":"Mult Scler Relat Disord"},{"key":"897_CR18","doi-asserted-by":"crossref","unstructured":"Potticary H, Langdon D. A Systematic Review and Meta-Analysis of the Brief Cognitive Assessment for Multiple Sclerosis (BICAMS) International Validations. J Clin Med. 2023;12(2).","DOI":"10.3390\/jcm12020703"},{"issue":"10","key":"897_CR19","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/S1474-4422(20)30277-5","volume":"19","author":"RHB Benedict","year":"2020","unstructured":"Benedict RHB, Amato MP, DeLuca J, Geurts JJG. Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues. Lancet Neurol. 2020;19(10):860\u201371.","journal-title":"Lancet Neurol"},{"issue":"7","key":"897_CR20","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1177\/13524585211049397","volume":"28","author":"Z Weinstock","year":"2022","unstructured":"Weinstock Z, Morrow S, Conway D, Fuchs T, Wojcik C, Unverdi M, et al. Interpreting change on the Symbol Digit Modalities Test in people with relapsing multiple sclerosis using the reliable change methodology. Mult Scler. 2022;28(7):1101\u201311.","journal-title":"Mult Scler"},{"issue":"1","key":"897_CR21","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/bpa.12220","volume":"25","author":"GC DeLuca","year":"2015","unstructured":"DeLuca GC, Yates RL, Beale H, Morrow SA. Cognitive impairment in multiple sclerosis: clinical, radiologic and pathologic insights. Brain Pathol. 2015;25(1):79\u201398.","journal-title":"Brain Pathol"},{"issue":"2","key":"897_CR22","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s11136-021-02927-w","volume":"31","author":"TA Crouch","year":"2022","unstructured":"Crouch TA, Reas HE, Quach CM, Erickson TM. Does depression in multiple sclerosis mediate effects of cognitive functioning on quality of life? Qual Life Res. 2022;31(2):497\u2013506.","journal-title":"Qual Life Res"},{"issue":"10","key":"897_CR23","doi-asserted-by":"publisher","first-page":"5382","DOI":"10.1007\/s00415-022-11193-w","volume":"269","author":"M Filippi","year":"2022","unstructured":"Filippi M, Amato MP, Centonze D, Gallo P, Gasperini C, Inglese M, et al. Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. J Neurol. 2022;269(10):5382\u201394.","journal-title":"J Neurol"},{"issue":"6","key":"897_CR24","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1093\/qjmed\/hcx070","volume":"111","author":"N McNicholas","year":"2018","unstructured":"McNicholas N, O\u2019Connell K, Yap SM, Killeen RP, Hutchinson M, McGuigan C. Cognitive dysfunction in early multiple sclerosis: a review. QJM. 2018;111(6):359\u201364.","journal-title":"QJM"},{"issue":"1","key":"897_CR25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1159\/000047940","volume":"47","author":"Y Barak","year":"2002","unstructured":"Barak Y, Achiron A. Effect of interferon-beta-1b on cognitive functions in multiple sclerosis. Eur Neurol. 2002;47(1):11\u20134.","journal-title":"Eur Neurol"},{"issue":"11","key":"897_CR26","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1177\/13524585221089534","volume":"28","author":"T Sprenger","year":"2022","unstructured":"Sprenger T, Kappos L, Sormani MP, Miller AE, Poole EM, Cavalier S, et al. Effects of teriflunomide treatment on cognitive performance and brain volume in patients with relapsing multiple sclerosis: post hoc analysis of the TEMSO core and extension studies. Mult Scler. 2022;28(11):1719\u201328.","journal-title":"Mult Scler"},{"issue":"12","key":"897_CR27","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s40263-022-00965-7","volume":"36","author":"L Freeman","year":"2022","unstructured":"Freeman L, Longbrake EE, Coyle PK, Hendin B, Vollmer T. High-Efficacy therapies for treatment-Naive individuals with relapsing-remitting multiple sclerosis. CNS Drugs. 2022;36(12):1285\u201399.","journal-title":"CNS Drugs"},{"key":"897_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104553","volume":"71","author":"S Levy","year":"2023","unstructured":"Levy S, Dvorak EM, Graney R, Staker E, Sumowski JF. In-person and remote administrations of the symbol digit modalities test are interchangeable among persons with multiple sclerosis. Mult Scler Relat Disord. 2023;71:104553.","journal-title":"Mult Scler Relat Disord"},{"key":"897_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102559","volume":"46","author":"A Renner","year":"2020","unstructured":"Renner A, Baetge SJ, Filser M, Penner IK. Working ability in individuals with different disease courses of multiple sclerosis: factors beyond physical impairment. Mult Scler Relat Disord. 2020;46:102559.","journal-title":"Mult Scler Relat Disord"},{"issue":"13","key":"897_CR30","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1177\/1352458518808204","volume":"25","author":"L Strober","year":"2019","unstructured":"Strober L, DeLuca J, Benedict RH, Jacobs A, Cohen JA, Chiaravalloti N, et al. Symbol Digit Modalities Test: A valid clinical trial endpoint for measuring cognition in multiple sclerosis. Mult Scler. 2019;25(13):1781\u201390.","journal-title":"Mult Scler"},{"issue":"2","key":"897_CR31","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1212\/01.WNL.0000129828.03714.90","volume":"63","author":"SC Huijbregts","year":"2004","unstructured":"Huijbregts SC, Kalkers NF, de Sonneville LM, de Groot V, Reuling IE, Polman CH. Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS. Neurology. 2004;63(2):335\u20139.","journal-title":"Neurology"},{"key":"897_CR32","unstructured":"Benedict RHB, Penner IK, Cutter G, Kappos L, Coyle P, Piani-Meier D, et al. Improvement in cognitive processing speed with ofatumumab in patients with relapsing multiple sclerosis. Oral presentation at the 8th European Academy of Neurology (EAN) Congress; June 25\u201328, 2022; Vienna, Austria. OPR-130"},{"issue":"1","key":"897_CR33","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s12883-019-1337-z","volume":"19","author":"J Perumal","year":"2019","unstructured":"Perumal J, Fox RJ, Balabanov R, Balcer LJ, Galetta S, Makh S, et al. Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE. BMC Neurol. 2019;19(1):116.","journal-title":"BMC Neurol"},{"key":"897_CR34","doi-asserted-by":"publisher","first-page":"730","DOI":"10.3389\/fneur.2017.00730","volume":"8","author":"E Riepl","year":"2017","unstructured":"Riepl E, Pfeuffer S, Ruck T, Lohmann H, Wiendl H, Meuth SG, et al. Alemtuzumab Improves Cognitive Processing Speed in Active Multiple Sclerosis-A Longitudinal Observational Study. Front Neurol. 2017;8:730.","journal-title":"Front Neurol"},{"key":"897_CR35","doi-asserted-by":"crossref","unstructured":"Benedict RHB, Arnold DL, Cree BAC, Meng X, Schofield L, Boulos F, et al. Improved processing speed on fingolimod therapy: oral Symbol Digit Modalities Test response in PREFERMS. Poster presented at the 69th Annual Meeting of the American Academy of Neurology's (AAN); April 22\u201328, 2017; Boston, MA, USA. P4.331.","DOI":"10.1212\/WNL.88.16_supplement.P4.331"},{"key":"897_CR36","unstructured":"Benedict RHB, Vermersch P, Buffels R, Wei W, Hartung H-P. Baseline cognitive functioning using the Brief International Cognitive Assessment for MS (BICAMS) Tests in patients with relapsing-remitting multiple sclerosis enrolled in phase IIIb studies of ocrelizumab (ENSEMBLE and CASTING). Poster presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); September 11\u201313, 2019; Stockholm, Sweden. P1170."},{"key":"897_CR37","unstructured":"Benedict RHB, Comi G, Oreja-Guevara C, Siva A, Van Wijmeersch B, Wiendl H, et al. Cognitive improvements in ocrelizumab-treated patients with relapsing-remitting multiple sclerosis: 96-week CASTING study data. Poster presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); October 26\u201328, 2022; Amsterdam, The Netherlands. P377."},{"issue":"4-5","key":"897_CR38","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1177\/13524585231153992","volume":"29","author":"A Manouchehrinia","year":"2023","unstructured":"Manouchehrinia A, Larsson H, Karim ME, Lycke J, Olsson T, Kockum I. Comparative effectiveness of natalizumab on cognition in multiple sclerosis: a cohort study. Mult Scler. 2023;29(4\u20135):628\u201336.","journal-title":"Mult Scler"},{"key":"897_CR39","unstructured":"Vermersch P, Wiendl H, Barkhof F, Montalban X, Achiron A, Derfuss T, et al. Improved Cognitive Processing Speed in Patients Treated With Cladribine Tablets for Multiple Sclerosis: MAGNIFY-MS 2-year Findings. Poster presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum. February 29\u2013March 02, 2024; West Palm Beach, FL, USA. P070."},{"key":"897_CR40","doi-asserted-by":"crossref","unstructured":"Benedict RHB, Sormani MP, McGinley M, Arnold D, Bar-Or A, Bermel R, et al. A multicenter , open label, single arm, phase 3b study (CONSONANCE) to assess the efficacy of ocrelizumab in patients with primary and secondary progressive multiple sclerosis: Year 1 interim analysis of cognition outcomes. Poster presented at the 74th Annual Meeting of the American Academy of Neurology (AAN); April 2\u20137, 2022; Seattle, WA, USA. P1.289.","DOI":"10.1212\/WNL.98.18_supplement.647"},{"key":"897_CR41","doi-asserted-by":"crossref","unstructured":"Benedict RHB, De Seze J, Hauser S, Kappos L, Wolinsky J, Zheng H, et al. Impact of ocrelizumab on cognition in patients at increased risk of progressive disease. Neurology. 2018;90.","DOI":"10.1212\/WNL.90.15_supplement.P1.420"},{"issue":"P5","key":"897_CR42","first-page":"356","volume":"2017","author":"Berkovich R. Effects of alemtuzumab on disability and cognition in patients with secondary progressive multiple sclerosis (SPMS). Poster presented at the 69th Annual Meeting of the American Academy of Neurology (AAN); April 22\u201328","year":"2017","unstructured":"Berkovich R. Effects of alemtuzumab on disability and cognition in patients with secondary progressive multiple sclerosis (SPMS). Poster presented at the 69th Annual Meeting of the American Academy of Neurology (AAN); April 22\u201328. Boston, Massachusetts. USA. 2017;2017(P5):356.","journal-title":"USA"},{"issue":"12","key":"897_CR43","doi-asserted-by":"publisher","first-page":"4135","DOI":"10.1111\/ene.15081","volume":"28","author":"DW Langdon","year":"2021","unstructured":"Langdon DW, Tomic D, Penner IK, Calabrese P, Cutter G, Haring DA, et al. Baseline characteristics and effects of fingolimod on cognitive performance in patients with relapsing-remitting multiple sclerosis. Eur J Neurol. 2021;28(12):4135\u201345.","journal-title":"Eur J Neurol"},{"issue":"1","key":"897_CR44","first-page":"93","volume":"87","author":"N De Stefano","year":"2016","unstructured":"De Stefano N, Stromillo ML, Giorgio A, Bartolozzi ML, Battaglini M, Baldini M, et al. Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2016;87(1):93\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"Suppl 1","key":"897_CR45","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/j.msard.2016.07.003","volume":"9","author":"G Giovannoni","year":"2016","unstructured":"Giovannoni G, Butzkueven H, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, et al. Brain health: time matters in multiple sclerosis. Mult Scler Relat Disord. 2016;9(Suppl 1):S5\u201348.","journal-title":"Mult Scler Relat Disord"},{"key":"897_CR46","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.msard.2018.03.002","volume":"21","author":"R Ouellette","year":"2018","unstructured":"Ouellette R, Bergendal A, Shams S, Martola J, Mainero C, Kristoffersen Wiberg M, et al. Lesion accumulation is predictive of long-term cognitive decline in multiple sclerosis. Mult Scler Relat Disord. 2018;21:110\u20136.","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"897_CR47","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/s002340000500","volume":"43","author":"R Zivadinov","year":"2001","unstructured":"Zivadinov R, De Masi R, Nasuelli D, Bragadin LM, Ukmar M, Pozzi-Mucelli RS, et al. MRI techniques and cognitive impairment in the early phase of relapsing-remitting multiple sclerosis. Neuroradiology. 2001;43(4):272\u20138.","journal-title":"Neuroradiology"},{"issue":"5","key":"897_CR48","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1080\/13696998.2016.1277229","volume":"20","author":"A Salter","year":"2017","unstructured":"Salter A, Thomas N, Tyry T, Cutter G, Marrie RA. Employment and absenteeism in working-age persons with multiple sclerosis. J Med Econ. 2017;20(5):493\u2013502.","journal-title":"J Med Econ"},{"issue":"1","key":"897_CR49","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s10926-019-09850-5","volume":"30","author":"CH Marck","year":"2020","unstructured":"Marck CH, Aitken Z, Simpson S Jr., Weiland TJ, Kavanagh A, Jelinek GA. Predictors of change in employment status and associations with quality of life: a prospective international study of people with multiple sclerosis. J Occup Rehabil. 2020;30(1):105\u201314.","journal-title":"J Occup Rehabil"},{"key":"897_CR50","unstructured":"International Labour Organization (ILO). Uncertain and uneven recovery expected following unprecedented labour market crisis 2021. Accessed January 2026; Available from: www.ilo.org\/resource\/news\/ilo-uncertain-and-uneven-recovery-expected-following-unprecedented-labour#2."},{"issue":"3","key":"897_CR51","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1007\/s10926-023-10149-9","volume":"34","author":"M Ponzio","year":"2024","unstructured":"Ponzio M, Podda J, Pignattelli E, Verri A, Persechino B, Vitturi BK, et al. Work Difficulties in People with Multiple Sclerosis. J Occup Rehabil. 2024;34(3):606\u201317.","journal-title":"J Occup Rehabil"},{"key":"897_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102512","volume":"46","author":"AC Vogel","year":"2020","unstructured":"Vogel AC, Schmidt H, Loud S, McBurney R, Mateen FJ. Impact of the COVID-19 pandemic on the health care of >1,000 people living with multiple sclerosis: a cross-sectional study. Mult Scler Relat Disord. 2020;46:102512.","journal-title":"Mult Scler Relat Disord"},{"key":"897_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1217843","volume":"11","author":"BK Vitturi","year":"2023","unstructured":"Vitturi BK, Rahmani A, Montecucco A, Dini G, Durando P. Occupational outcomes of people with multiple sclerosis during the COVID-19 pandemic: a systematic review with meta-analysis. Front Public Health. 2023;11:1217843.","journal-title":"Front Public Health"},{"issue":"1","key":"897_CR54","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1212\/WNL.0000000000207301","volume":"101","author":"N Castrogiovanni","year":"2023","unstructured":"Castrogiovanni N, Mostert J, Repovic P, Bowen JD, Uitdehaag BMJ, Strijbis EMM, et al. Longitudinal changes in cognitive test scores in patients with relapsing-remitting multiple sclerosis: an analysis of the DECIDE dataset. Neurology. 2023;101(1):e1\u201311.","journal-title":"Neurology"},{"key":"897_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102577","volume":"46","author":"E Skorve","year":"2020","unstructured":"Skorve E, Lundervold AJ, Torkildsen O, Myhr KM. A two-year longitudinal follow-up of cognitive performance assessed by BICAMS in newly diagnosed patients with MS. Mult Scler Relat Disord. 2020;46:102577.","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"897_CR56","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.1097\/WNO.0000000000001280","volume":"42","author":"S Collorone","year":"2022","unstructured":"Collorone S, Kanber B, Hashem L, Cawley N, Prados F, Davagnanam I, et al. Visual function and brief cognitive assessment for multiple sclerosis in optic neuritis clinically isolated syndrome patients. J Neuroophthalmol. 2022;42(1):e22\u201331.","journal-title":"J Neuroophthalmol"},{"issue":"1","key":"897_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-018-1065-9","volume":"18","author":"J Frau","year":"2018","unstructured":"Frau J, Fenu G, Signori A, Coghe G, Lorefice L, Barracciu MA, et al. A cross-sectional and longitudinal study evaluating brain volumes, RNFL, and cognitive functions in MS patients and healthy controls. BMC Neurol. 2018;18(1):67.","journal-title":"BMC Neurol"},{"key":"897_CR58","volume":"2014","author":"SM Rao","year":"2014","unstructured":"Rao SM, Martin AL, Huelin R, Wissinger E, Khankhel Z, Kim E, et al. Correlations between MRI and information processing speed in MS: a meta-analysis. Mult Scler Int. 2014;2014:975803.","journal-title":"Mult Scler Int"},{"key":"897_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104398","volume":"69","author":"E Skorve","year":"2023","unstructured":"Skorve E, Lundervold AJ, Torkildsen O, Riemer F, Gruner R, Myhr KM. Brief international cognitive assessment for MS (BICAMS) and global brain volumes in early stages of MS - a longitudinal correlation study. Mult Scler Relat Disord. 2023;69:104398.","journal-title":"Mult Scler Relat Disord"},{"key":"897_CR60","unstructured":"ClinicalTrials.gov. Cognition and HRQoL in adults with highly-active RMS in Year 3 and 4 after initial Mavenclad\u00ae dose (CLARIFY-MS Extension) 2024. Accessed January 2026; Available from: clinicaltrials.gov\/ct2\/show\/NCT04776213."}],"updated-by":[{"DOI":"10.1007\/s40120-026-00963-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000}}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00897-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-00897-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00897-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:11:20Z","timestamp":1784819480000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-00897-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["897"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-00897-0","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"3 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: to correct the sentence starting \"When considering a \u2265 8-point change\u2026\"","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40120-026-00963-7","URL":"https:\/\/doi.org\/10.1007\/s40120-026-00963-7","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following potential conflicts of interest: Bruno Brochet has received consultancy fees and speaker fees from Merck and Sanofi. Dawn Langdon has participated in speaker bureaus for Almirall, Bayer, Biogen, Bristol Myers Squibb (BMS), Merck, Novartis, Roche, Sanofi, and Teva; has received consultancy fees from Bayer, Biogen, BMS, Merck, Novartis, and Teva; and has received research grants from Bayer, Biogen, Merck, and Novartis. Dawn Langdon is an Editorial Board member of\n                      Neurology and Therapy\n                      , and was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Eva Kubala Havrdova received financial support for conference travel, and\/or speaker honoraria, and\/or research support, and\/or consultant fees from Actelion, Biogen, Celgene, Merck, Novartis, Roche, Sanofi, and Teva. She has been supported by the Czech Ministry of Education\u2014project Cooperatio LF1, research area Neuroscience\u2014and by the General University Hospital in Prague project MH CZ-DRO-VFN64165. Jeanette Lechner-Scott has received travel compensation from Biogen, Merck, and Novartis. Her institution receives honoraria for talks and advisory board commitments as well as research grants from Biogen, Merck, Novartis, and Roche. Xavier Montalban's institution has received compensation for lecture honoraria and travel expenses, participation in scientific meetings, clinical trial steering committee membership, or clinical advisory board participation in recent years from AbbVie, Actelion, Alexion, AstraZeneca, Autolus, Bial PD, Biogen, BMS\/Celgene, Genzyme, Hoffmann-La Roche, Immunic Therapeutics, Indivi, Janssen Pharmaceuticals, Juvis\u00e9 Pharmaceutical, Lilly, MedDay, Medscape, Merck, Mylan-Viatris, Nervgen, Neuraxpharm, Novartis, PeerVoice, Rewind Therapeutics, Samsung-Biosys, Sandoz, Sanofi-Genzyme, Teva Pharmaceutical, TG Therapeutics, Zenas Biopharma, Excemed, ECTRIMS, MSIF, and NMSS, or any of their affiliates. Francesco Patti has received personal compensation for speaking activities or serving on advisory boards from Alexion, Almirall, Biogen, BMS, Johnson & Johnson, Merck, Novartis, Roche, and Sanofi. He has also received research grants from Alexion, Almirall, the Italian Ministry of Health, Merck, MIUR, Novartis, Roche, and Sanofi. He is Associate Editor of\n                      Frontiers in Neurology\n                      . Francesco Patti is an Editorial Board member of\n                      Neurology and Therapy\n                      . He was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Fredrik Piehl has received research grants from Janssen, Merck, and Sanofi; fees for serving as a member of the DMC in clinical trials with Lundbeck, Parexel, and Roche; and fees for the preparation of witness statements for Novartis. Alessandra Solari has served on advisory boards for Almirall and Merck and has been invited to speak on behalf of the same companies. She has also received research grants from the Italian MS Society. Raymond Hupperts has received institutional research grants and fees for lectures and advisory boards from Biogen, Merck, and Sanofi. Nektaria Alexandri, Annette Lehn, and Andrzej Smyk are employees of Merck Healthcare KGaA, Darmstadt, Germany. Krzysztof Selmaj has received honoraria for speaking, consulting, and serving on advisory boards for Biogen, Celgene (BMS), Merck, Novartis, Roche, and TG Therapeutics.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The CLARIFY-MS study was conducted in accordance with the principles outlined in the Declaration of Helsinki and the International Council for Harmonisation Guidelines for Good Clinical Practice. This study was approved by independent ethics committees or institutional review boards at each study site. Participants provided written informed consent prior to the initiation of any study-related activities. Details of all institutional review boards and ethics committees are available in Supplementary Table S5.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}